Search Results

University of Calgary research demonstrates more than 200-fold improvement in antibacterial performance while Biosenta advances commercialization

Nature Communications Publishes Breakthrough Study Showing How COVID-Era Immune Memory Can Be Redirected to Fight Cancer Celloram, Inc., University Hospitals, and Case Western Reserve University unveil PROTEXI, a novel cancer vaccine platform advancing toward first-in-human clinical trials in sarcoma patients.

Acceptance of TempraMed’s products by Meuhedet Health Services strengthens TempraMed’s B2B institutional commercialization strategy as the Company advances reimbursement initiatives and expands relationships with leading healthcare organizations globally Highlights Meuhedet Health Services, Israel’s third-largest Health Maintenance Organization (HMO), serving more than one million insured members, has accepted TempraMed’s flagship VIVI Cap™ and VIVI Epi™ products. TempraMed products are now accepted by two of Israel’s four national HMOs—Maccabi Healthcare Services and Meuhedet—providing institutional access to approximately four million insured lives. The Company is executing a global B2B institutional strategy focused on healthcare organizations, insurers, distributors and government healthcare systems.